Press Releases

 
Press Releases
Date Title and Summary View
May 15, 2012 First Patient Enrolled in Second Cohort, Additional Clinical Results Expected in Q3 2012 Expects to Begin Phase 2 Proof-of-Concept Trials in Q1 2013 MADISON, WI, May 15, 2012 – Novelos Therapeutics, Inc. (OTCQX: NVLT), a pharmaceutical company developing novel...
PDF
Apr 24, 2012 Demonstrates Positive Initial Imaging Results; Additional Clinical Results Expected by mid-2012 MADISON, WI, April 24, 2012 – Novelos Therapeutics, Inc. (OTCQX: NVLT), a pharmaceutical company developing novel drugs for treatment and diagnosis of cancer, today announced that the University o...
PDF
Apr 3, 2012 Broad-Spectrum, Cancer-Targeting Therapeutic and Diagnostic Agents Described MADISON, WI, April 3, 2012 – Novelos Therapeutics, Inc. (OTCQX: NVLT), a pharmaceutical company developing novel drugs for treatment and diagnosis of cancer, today announced that three scientific posters based on research con...
PDF
Mar 15, 2012 Expects Initial Imaging Results in the Second Quarter of 2012 MADISON, WI, March 15, 2012 – Novelos Therapeutics, Inc. (OTCQX: NVLT), a pharmaceutical company developing novel drugs for treatment and diagnosis of cancer, today announced that the University of Wisconsin Carbone Cancer Center...
PDF
Mar 1, 2012 Broad-Spectrum, Cancer-Targeting Therapeutic and Diagnostic Agents Described MADISON, WI, March 1, 2012 – Novelos Therapeutics, Inc. (OTCQX: NVLT), a pharmaceutical company developing novel drugs for treatment and diagnosis of cancer, today announced that three scientific posters based on r...
PDF
Dec 1, 2011 MADISON, WI, December 1, 2011 – Novelos Therapeutics, Inc. (OTCBB: NVLT), a pharmaceutical company developing novel drugs for treatment and diagnosis of cancer, today announced the pricing of an underwritten public offering of 9,840,000 units at $0.60 per unit for gross proceeds of $5,904,000. Each unit consists of one share of common stock an...
PDF
Oct 19, 2011 MADISON, WI, October 19, 2011 – Novelos Therapeutics, Inc. (OTCBB: NVLT), a pharmaceutical company developing novel drugs for treatment and diagnosis of cancer, today announced that on October 17, 2011, Judge Judith Fabricant granted Novelos' motion for judgment on the pleadings in the action brought in the Business Litigation Session of the M...
PDF
Sep 6, 2011 MADISON, WI, September 6, 2011 – Novelos Therapeutics, Inc. (OTCBB: NVLT), a pharmaceutical company developing novel drugs for treatment and diagnosis of cancer, today announced that Harry S. Palmin, President and CEO of Novelos, will present at the Rodman & Renshaw 13th Annual Healthcare Conference on Monday, September 12, 2011. Mr. Palmin is...
PDF
Jun 28, 2011 MADISON, WI, June 28, 2011 – Novelos Therapeutics, Inc. (OTCBB: NVLT), a pharmaceutical company developing novel drugs for treatment and diagnosis of cancer, today announced that on June 23, 2011, Judge Nathaniel M. Gorton allowed the defendants' motion to dismiss the putative federal securities fraud class action brought in the United States ...
PDF
Jun 13, 2011 MADISON, WI, June 13, 2011 – Novelos Therapeutics, Inc. (OTCBB: NVLT), a pharmaceutical company developing novel drugs for treatment and diagnosis of cancer, today announced that Harry S. Palmin, President and CEO of Novelos, will present at the 5th Lippert/Heilshorn Life Sciences & Medical Technologies Virtual Conference on Thursday, June 16,...
PDF
Page: FirstPrevious ...
16
NextLast